20 Eastbourne Terrace
About LivaNova PLCLivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
CEO: Damien McDonald
CFO: Vivid Sehgal
Please click here for LivaNova job opportunities.
88 articles with LivaNova PLC
LivaNova PLC, a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2019 results on Wednesday, October 30, 2019 at 12 p.m. London time.
LivaNova PLC announced the first patient enrolled in “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression”.
LivaNova to Present Updates on Autonomic Regulation Therapy at the 23rd Annual Scientific Meeting of the Heart Failure Society of America
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present a summary of implantable neuromodulation technology for patients with heart failure during the 23rd Annual Scientific Meeting of the Heart Failure Society of America, September 13 – 16, Pennsylvania Convention Center, Philadelphia.
LivaNova Receives Approval from U.S. Centers for Medicare & Medicaid Services for RECOVER Clinical Study
Study to evaluate VNS Therapy for Treatment-Resistant Depression in accordance with agency’s National Coverage Determination as part of its Coverage with Evidence Development Program
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended June 30, 2019.
The inclination of patients and surgeons toward MI procedures using thoracic catheters is increasing significantly owing to the severe complications associated with traditional open surgeries.
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery.
The versatile and compact system offers the power and simplicity to support more patients in more places
Revolutionary therapy system has treated more than 120,000 patients worldwide
LivaNova PLC announced that Stacy Enxing Seng, a Venture Partner with Lightstone Ventures and former executive at several healthcare and medical technology companies, was elected by the Company’s shareholders to join its Board of Directors during its June 18 annual general meeting.
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second quarter 2019 results on Wednesday, July 31, 2019 at 1 p.m. London time (8 a.m. Eastern Daylight Time).
LivaNova PLC announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the Jefferies Healthcare Conference on Tuesday, June 4 in New York at 11 a.m. Eastern Time.
LivaNova PLC announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New York at 10 a.m. Eastern Time.
New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting
Key findings from study at Leuven University Hospital show no explants due to structural valve deterioration in 11 years of Perceval use
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended March 31, 2019.
Results for the quarter ended March 31, 2019.
Replays of the webcast will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event.
LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device.
Hebbelinck will lead global human resources, serve on the Executive Leadership Team and report to Chief Executive Officer Damien McDonald.
LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology 68th Annual Scientific Session (ACC 2019) from March 16-18 in New Orleans, USA.